All In Biotech

Drug Trial Radar · NCT03905525

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

A 48-week, 6-arm, Randomized, Double-blind, Placebo-controlled Multicenter Trial to Assess the Safety and Efficacy of Multiple CFZ533 Doses Administered Subcutaneously in Two Distinct Populations of Patients With Sjogren's Syndrome (TWINSS)

Last checked: Nov 19, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 273 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

273

Actual

Start

Oct 1, 2019

Primary completion

Sep 28, 2022

Study completion Jun 6, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).

Conditions

  • Sjögren Syndrome

Interventions

  • CFZ533Drug

    Biological

  • PlaceboOther

    liquid placebo for injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Change in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) Score From Baseline at 24 Weeks as Compared to PlaceboTime frame: Baseline, Week 24
  2. Cohort 2: Change in EULAR Sjögren Syndrome Patient Reported Index (ESSPRI) Score From Baseline at 24 Weeks as Compared to Placebo.Time frame: Baseline, Week 24

Locations

71 sites in 23 countries. Site status is shown where the registry gives one.

  • North GA Rheumatology Group PC

    Suwanee, Georgia

  • Indiana Univ School of Dentistry

    Indianapolis, Indiana

  • Ochsner Health System

    Baton Rouge, Louisiana

  • The John Hopkins Jerome L Greene Sjogren

    Baltimore, Maryland

  • Tufts School of Dental Medicine

    Boston, Massachusetts

  • Winthrop University Hospital

    Mineola, New York

  • Perelman School of Medicine

    Philadelphia, Pennsylvania

  • Uni Wisconsin School Med Pub Health

    Madison, Wisconsin

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Vitória, Espírito Santo, Brazil

  • Novartis Investigative Site

    Juiz de Fora, Minas Gerais, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Rimouski, Quebec, Canada

  • Novartis Investigative Site

    Trois-Rivières, Quebec, Canada

  • Novartis Investigative Site

    Concepción, Chile

  • Novartis Investigative Site

    Valdivia, Los Ríos Region, Chile

  • Novartis Investigative Site

    Santiago, RM, Chile

  • Novartis Investigative Site

    Santiago, Santiago Metropolitan, Chile

  • Novartis Investigative Site

    Santiago, Santiago Metropolitan, Chile

  • Novartis Investigative Site

    Medellín, Antioquia, Colombia

  • Novartis Investigative Site

    Barranquilla, Atlántico, Colombia

  • Novartis Investigative Site

    Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site

    Brest, France

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, Germany

  • Novartis Investigative Site

    Dresden, Saxony, Germany

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Szeged, Hungary

  • Novartis Investigative Site

    Székesfehérvár, Fejér, Hungary

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.